[{"id":"917b48fd-6760-442b-9dca-351ad6f6d491","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299141","created_at":"2021-01-17T17:53:09.705Z","updated_at":"2025-02-25T15:33:17.802Z","phase":"Phase 2","brief_title":"Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02299141","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • ALK • TP53 • FLT1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • RET rearrangement","tags":["EGFR • ALK • TP53 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/07/2015","start_date":" 05/07/2015","primary_txt":" Primary completion: 01/09/2020","primary_completion_date":" 01/09/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-11"},{"id":"727643b8-a896-41d1-b305-2893939501cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04631744","created_at":"2021-01-19T20:36:38.297Z","updated_at":"2025-02-25T17:30:30.138Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04631744","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4","pipe":"","alterations":" ","tags":["FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-01-31"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"2724193d-44df-4903-9b86-2f4db953b4cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06075849","created_at":"2023-11-19T04:16:12.935Z","updated_at":"2024-07-02T16:35:17.893Z","phase":"Phase 1","brief_title":"Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent","source_id_and_acronym":"NCT06075849","lead_sponsor":"Panolos Bioscience","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PB101"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-23"},{"id":"68aa0036-1540-4538-858b-bf876fa2e9ec","acronym":"RACING","url":"https://clinicaltrials.gov/study/NCT03745430","created_at":"2021-01-18T18:20:40.965Z","updated_at":"2025-02-25T14:27:50.093Z","phase":"Phase 1/2","brief_title":"RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03745430 - RACING","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9","pipe":" | ","alterations":" EGFR mutation • PTEN mutation","tags":["PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 04/23/2023","study_completion_date":" 04/23/2023","last_update_posted":"2023-05-24"},{"id":"cfec14aa-1813-413d-8c1f-46e334b4c105","acronym":"","url":"https://clinicaltrials.gov/study/NCT01385059","created_at":"2021-01-18T05:40:56.063Z","updated_at":"2024-07-02T16:35:53.943Z","phase":"Phase 2","brief_title":"Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer","source_id_and_acronym":"NCT01385059","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 10/28/2011","start_date":" 10/28/2011","primary_txt":" Primary completion: 10/09/2013","primary_completion_date":" 10/09/2013","study_txt":" Completion: 10/09/2013","study_completion_date":" 10/09/2013","last_update_posted":"2023-03-07"},{"id":"3a1a5254-3234-4524-b5ba-287fea6ff089","acronym":"","url":"https://clinicaltrials.gov/study/NCT03823651","created_at":"2021-03-02T16:53:11.206Z","updated_at":"2024-07-02T16:35:58.847Z","phase":"","brief_title":"A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP)","source_id_and_acronym":"NCT03823651","lead_sponsor":"Duke University","biomarkers":" IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16","pipe":"","alterations":" ","tags":["IL6 • FLT1 • IL2 • IL10 • VEGFC • FGF • IL17A • IL23A • IL17C • IL21 • IL22 • TSLP • VCAM1 • IL16"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/27/2019","start_date":" 06/27/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-12-20"},{"id":"0c90cd30-d9b5-4626-af27-72cee25782de","acronym":"REBORN","url":"https://clinicaltrials.gov/study/NCT04464122","created_at":"2021-01-18T21:27:30.836Z","updated_at":"2024-07-02T16:36:00.020Z","phase":"","brief_title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","source_id_and_acronym":"NCT04464122 - REBORN","lead_sponsor":"University of Roma La Sapienza","biomarkers":" KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3","pipe":"","alterations":" ","tags":["KDR • IL6 • HIF1A • CXCL10 • FLT1 • CXCL9 • MMP2 • TIMP1 • VEGFC • CCL2 • TIMP2 • MMP9 • CXCL6 • FGF1 • IL1B • CHGA • CXCL1 • MMP14 • TIMP3"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 09/14/2024","primary_completion_date":" 09/14/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-11-23"},{"id":"20efeb70-a46d-4b47-9855-0576c986d562","acronym":"","url":"https://clinicaltrials.gov/study/NCT04374747","created_at":"2021-01-18T21:08:05.002Z","updated_at":"2024-07-02T16:36:00.953Z","phase":"","brief_title":"Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk","source_id_and_acronym":"NCT04374747","lead_sponsor":"University of Massachusetts, Amherst","biomarkers":" IL6 • TNFA • CXCL8 • FLT1 • VEGFD • FGF • IL1B • LEP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • FLT1 • VEGFD • FGF • IL1B • LEP"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/24/2019","start_date":" 10/24/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2022-11-04"},{"id":"863f301c-d7ce-401c-a561-44e816aa2de5","acronym":"BOOSTER","url":"https://clinicaltrials.gov/study/NCT01989780","created_at":"2021-01-18T09:04:26.431Z","updated_at":"2024-07-02T16:36:06.061Z","phase":"Phase 2","brief_title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","source_id_and_acronym":"NCT01989780 - BOOSTER","lead_sponsor":"Japan Breast Cancer Research Group","biomarkers":" HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2022-08-04"},{"id":"81732a4f-3390-49ea-a156-28fdbac06dce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02133742","created_at":"2021-01-18T09:54:06.406Z","updated_at":"2024-07-02T16:36:27.343Z","phase":"Phase 1b","brief_title":"A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer","source_id_and_acronym":"NCT02133742","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • mTOR • KDR • CXCL8 • FLT1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • mTOR • KDR • CXCL8 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • axitinib"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 09/16/2014","start_date":" 09/16/2014","primary_txt":" Primary completion: 03/31/2017","primary_completion_date":" 03/31/2017","study_txt":" Completion: 07/03/2019","study_completion_date":" 07/03/2019","last_update_posted":"2021-07-28"},{"id":"4f4a1258-59e4-47e2-9c5f-489bd6ceb50d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01620970","created_at":"2021-05-14T19:09:31.306Z","updated_at":"2024-07-02T16:36:30.269Z","phase":"Phase 2","brief_title":"PF-03446962 in Relapsed or Refractory Urothelial Cancer","source_id_and_acronym":"NCT01620970","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" EGFR • HER-2 • PTEN • KIT • IL6 • FLT1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • PTEN • KIT • IL6 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ascrinvacumab (GT90001)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2021-05-14"},{"id":"931a0803-d4c8-4f98-9bb6-97e87c40e482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01956669","created_at":"2021-01-18T08:52:55.254Z","updated_at":"2024-07-02T16:36:42.063Z","phase":"Phase 2","brief_title":"Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors","source_id_and_acronym":"NCT01956669","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KIT • KDR • AFP • FLT1 • VEGFC • FGF","pipe":"","alterations":" ","tags":["KIT • KDR • AFP • FLT1 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/08/2014","start_date":" 10/08/2014","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 11/05/2019","study_completion_date":" 11/05/2019","last_update_posted":"2020-08-12"},{"id":"91d2c7e7-7017-45f1-805f-8e73462eafcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01283945","created_at":"2021-01-18T05:12:34.871Z","updated_at":"2024-07-02T16:36:51.882Z","phase":"Phase 1/2","brief_title":"Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors","source_id_and_acronym":"NCT01283945","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" FGFR1 • KDR • VEGFA • FLT1","pipe":" | ","alterations":" FGFR1 amplification","tags":["FGFR1 • KDR • VEGFA • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lucitanib (E 3810)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 05/04/2017","study_completion_date":" 05/04/2017","last_update_posted":"2020-01-03"},{"id":"84532115-f132-4343-92be-f79abab8db7d","acronym":"TIVA/TCI-BC","url":"https://clinicaltrials.gov/study/NCT02839668","created_at":"2021-01-18T13:56:02.014Z","updated_at":"2024-07-02T16:36:54.184Z","phase":"Phase 2","brief_title":"The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC)","source_id_and_acronym":"NCT02839668 - TIVA/TCI-BC","lead_sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","biomarkers":" KDR • VEGFA • FLT1","pipe":"","alterations":" ","tags":["KDR • VEGFA • FLT1"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 09/01/2019","study_completion_date":" 09/01/2019","last_update_posted":"2019-10-29"},{"id":"3ede8ad2-acee-4e50-a570-83fc9035aab8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01782313","created_at":"2021-01-18T07:51:26.424Z","updated_at":"2024-07-02T16:36:55.886Z","phase":"Phase 2","brief_title":"A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas","source_id_and_acronym":"NCT01782313","lead_sponsor":"Northwestern University","biomarkers":" KDR • FLT1","pipe":" | ","alterations":" KDR expression • FLT1 expression","tags":["KDR • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KDR expression • FLT1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 03/06/2013","start_date":" 03/06/2013","primary_txt":" Primary completion: 05/27/2015","primary_completion_date":" 05/27/2015","study_txt":" Completion: 12/28/2016","study_completion_date":" 12/28/2016","last_update_posted":"2019-09-09"},{"id":"5d6a13b7-0d2f-4bad-b517-6aad5b7c8e21","acronym":"","url":"https://clinicaltrials.gov/study/NCT01282463","created_at":"2021-01-18T05:12:09.851Z","updated_at":"2024-07-02T16:36:55.890Z","phase":"Phase 2","brief_title":"Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma","source_id_and_acronym":"NCT01282463","lead_sponsor":"Eli Lilly and Company","biomarkers":" KDR • FLT1 • VEGFB","pipe":"","alterations":" ","tags":["KDR • FLT1 • VEGFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Cyramza (ramucirumab) • icrucumab (IMC-18F1)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2019-09-09"},{"id":"d5003fdf-f2e7-4d91-8e0b-f087be500f33","acronym":"","url":"https://clinicaltrials.gov/study/NCT00569946","created_at":"2021-01-18T02:04:49.928Z","updated_at":"2024-07-02T16:36:59.082Z","phase":"Phase 2","brief_title":"Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)","source_id_and_acronym":"NCT00569946","lead_sponsor":"Pfizer","biomarkers":" KIT • KDR • VEGFA • FLT1 • FLT4","pipe":"","alterations":" ","tags":["KIT • KDR • VEGFA • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 12/12/2007","start_date":" 12/12/2007","primary_txt":" Primary completion: 02/26/2010","primary_completion_date":" 02/26/2010","study_txt":" Completion: 10/30/2012","study_completion_date":" 10/30/2012","last_update_posted":"2019-06-05"},{"id":"f1227737-a814-4556-a309-6f9739ca08f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01832259","created_at":"2021-01-18T08:09:04.311Z","updated_at":"2025-02-25T15:40:48.575Z","phase":"Phase 2","brief_title":"A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection","source_id_and_acronym":"NCT01832259","lead_sponsor":"University of Utah","biomarkers":" VEGFA • FLT1","pipe":"","alterations":" ","tags":["VEGFA • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 02/07/2017","primary_completion_date":" 02/07/2017","study_txt":" Completion: 08/09/2018","study_completion_date":" 08/09/2018","last_update_posted":"2018-12-12"},{"id":"8dd3f5a7-732d-4bef-9b49-824b3d62fff8","acronym":"EPHOS-B","url":"https://clinicaltrials.gov/study/NCT01104571","created_at":"2021-01-18T04:22:18.912Z","updated_at":"2025-02-25T15:51:00.378Z","phase":"Phase 3","brief_title":"Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer","source_id_and_acronym":"NCT01104571 - EPHOS-B","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" EGFR • HER-2 • ER • MYC • ERBB3 • FLT1 • CASP3 • CD31 • ENG • PECAM1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 amplification • HER-2 expression • ER negative","tags":["EGFR • HER-2 • ER • MYC • ERBB3 • FLT1 • CASP3 • CD31 • ENG • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 amplification • HER-2 expression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 257","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 08/30/2017","primary_completion_date":" 08/30/2017","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2018-09-17"},{"id":"b90c7697-6311-4262-9536-bc47534419d3","acronym":"AMALTHEA","url":"https://clinicaltrials.gov/study/NCT02129257","created_at":"2021-01-18T09:52:23.572Z","updated_at":"2024-07-02T16:37:16.932Z","phase":"Phase 2","brief_title":"Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT02129257 - AMALTHEA","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1","pipe":"","alterations":" ","tags":["KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 05/26/2014","start_date":" 05/26/2014","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 09/25/2017","study_completion_date":" 09/25/2017","last_update_posted":"2017-10-24"},{"id":"7145fa5e-0111-4f5b-9661-7b4fb6f2cf31","acronym":"REMMYDYS","url":"https://clinicaltrials.gov/study/NCT00744536","created_at":"2021-01-18T02:48:47.458Z","updated_at":"2025-02-25T14:26:16.015Z","phase":"Phase 2","brief_title":"Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS","source_id_and_acronym":"NCT00744536 - REMMYDYS","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 01/01/2012","primary_completion_date":" 01/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2017-06-09"},{"id":"fa153fa1-88be-494d-a000-63ab41769eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00454194","created_at":"2021-01-18T01:36:36.230Z","updated_at":"2024-07-02T16:37:24.233Z","phase":"Phase 2","brief_title":"Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00454194","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2017-03-21"},{"id":"2d2b9896-6ac4-41a2-a74d-d15eb0fe49c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00572728","created_at":"2021-01-18T02:05:27.772Z","updated_at":"2024-07-02T16:37:26.834Z","phase":"Phase 2","brief_title":"Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer","source_id_and_acronym":"NCT00572728","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 09/01/2014","primary_completion_date":" 09/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2016-12-30"}]